×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

BTK Inhibition for Waldenstrom Macroglobulinemia

Steven P. Treon, MD, PhD, shares his perspective on the evolving treatment landscape of Waldenström Macroglobulinemia. 
Episode 1 The Nature of Waldenstrom Macroglobulinemia
Steven P. Treon, MD, PhD, reviews the nature of Waldenström macroglobulinemia in the context of other non-Hodgkin lymphomas.
 
Episode 2 Risk Factors in Developing Waldenstrom Macroglobulinemia
Episode 3 Waldenstrom Macroglobulinemia: Establishing a Diagnosis
Episode 4 Factors Impacting a Diagnosis and Prognosis of WM
Episode 5 Waldenstrom Macroglobulinemia: When to Initiate Therapy
Episode 6 A Historic Perspective on Frontline WM Management
Episode 7 Waldenstrom Macroglobulinemia: Evolving Frontline Treatment
Episode 8 Selecting Therapy Through Multiple Lines in WM
Episode 9 Targeted Approaches in Waldenstrom Macroglobulinemia
Episode 10 BTK Inhibitors in WM: Understanding Safety/Efficacy
Episode 11 Future Management of Waldenstrom Macroglobulinemia
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×